Late-onset cTTP presenting in pregnancy
| Case . | Pregnancy . | Treatment given . | Outcomes . |
|---|---|---|---|
| 1 | 1. 21/40* | PI/PEX | IUFD |
| 2. 37/40 | PEX 2 weekly from 12 wk and 6 wk postpartum | Live birth | |
| 2 | 1. 20/40 | Stillbirth | |
| 2. FTND | LDA | Live birth | |
| 3. 10/40 | Miscarriage | ||
| 4. FTND | LDA | Live | |
| 5. FTND* | LDA and LMWH | Live | |
| 3 | 1. 35/40* | PEX | Live birth but severe developmental delay |
| 2. 36/40 | BPL 8Y from 12/40, 20 U/kg 2 weekly, increasing to 30 U/kg weekly from 25/40; PEX pre- and postdelivery; LDA and LMWH | Live birth | |
| 3. 11/40 | Miscarriage | ||
| 4. 36/40 | PEX every 2 wk, increased to weekly from mid–second trimester | Live birth | |
| 4 | First trimester* | 10/7 PEX until TTP remission, continued 3×/wk PEX until delivery; LDA; LMWH | Live 34/40 |
| 5 | 17/40* | Daily PEX, LDA, LMWH, steroids, rituximab | Live 30+/40 |
| 6† | 1. 37/40 | Steroids | Stillbirth |
| 2. 32/40 | FFP and steroids | IUFD | |
| 3. 32/40 | Live birth | ||
| 4. 33/40 (twins) | IUFD 33/40 | ||
| 7 | 1. 20/40 | IUFD | |
| 2. 31/40* | Daily PEX until remission, then weekly until 37/40 and postpartum | Live birth 37/40 | |
| 3. 23/40 | Daily PEX until remission, then every 2 wk until 31/40, PEX increased to twice weekly; 5 PEX postpartum | Live birth 38/40 | |
| 8 | 1. 25/40* | IUFD | |
| 2. 35/40 | PEX every 2 wk from 12 wk | Live birth | |
| 3. 8/40 | Miscarriage | ||
| 4. 34/40 | PEX every 2 wk from 12 wk; changed to BPL 8Y from 20/40 to delivery | Live birth | |
| 9 | 40/40* | PEX, LDA | Live birth |
| 10 | 37/40* | PEX, LDA | Live birth |
| 11 | 1. 14/40 | IUFD | |
| 2. 19/40 | IUFD | ||
| 3. 20/40 | IUFD | ||
| 4. 6/40 | Miscarriage | ||
| 5. 36/40* | Daily PEX and steroids | Live birth 37/40 | |
| 6. 37/40 | LDA and LMWH throughout; PI from 10/40 every 2 wk until 20 wk, then continued weekly; 1 PEX pre- and postdelivery | Live birth | |
| 12 | 1. 38/40* | PEX, LDA | Live birth |
| 2. 37/40 | PEX every 2 wk from 12 wk, continued with PI every 2 wk from second trimester | Live birth | |
| 13 | 1. 39/40* | PEX | Live birth |
| 2. 38/40 | Weekly PI in third trimester, LMWH, and LDA | Live birth | |
| 14 | 1. 27/40 | Platelet transfusion | Live birth |
| 2. 34/40* | PEX, steroids, LDA, LMWH, IVIg | Live birth | |
| 3. 36/40 | BPL 8Y ×2/wk throughout pregnancy and 4 wk postpartum; 2× PEX predelivery | Live birth | |
| 15 | 32/40* | Daily PEX to TTP remission then weekly until delivery | Live birth 37/40 |
| 16 | 1. 20/40 (twins) | IVIg, prednisolone, platelets, PEX | IUFD 25/40 |
| 2. 39/40 | PI throughout pregnancies; platelets at delivery | Live birth | |
| 3. 37/40 | Live birth | ||
| 4. 37/40* | Live birth | ||
| 17 | 14/40* | Daily PEX until remission, then weekly PEX to delivery | Live birth 35/40 |
| 18 | (Known from positive FH) | LDA, PI every 2 wk, then weekly from 25/40 | 37/40 |
| 19 | 1. 20/40 | IUFD | |
| 2. 24/40 (twins)* | IUFD | ||
| 3. 6/40 | Miscarriage | ||
| 4. 37/40 | Plasma treatment ×2/wk from 12 wk | Live birth | |
| 20 | 33/40 | Steroids | Live birth |
| 21 | 1. 34/40 (twins) | Platelets | Live birth |
| 2. 28/40* | PEX | Live 29/40 | |
| 22 | 1. 24/40 | IUFD | |
| 2. 26/40 | IUFD | ||
| 3. 27/40 | IUFD | ||
| 4, 5, 6. 6-12/40 | 3 miscarriages | ||
| 7. 27/40 | Live birth | ||
| 8. 20/40* | LDA, LMWH, PI, PEX | IUFD 28/40 | |
| 23† | 36/40 | Live birth |
| Case . | Pregnancy . | Treatment given . | Outcomes . |
|---|---|---|---|
| 1 | 1. 21/40* | PI/PEX | IUFD |
| 2. 37/40 | PEX 2 weekly from 12 wk and 6 wk postpartum | Live birth | |
| 2 | 1. 20/40 | Stillbirth | |
| 2. FTND | LDA | Live birth | |
| 3. 10/40 | Miscarriage | ||
| 4. FTND | LDA | Live | |
| 5. FTND* | LDA and LMWH | Live | |
| 3 | 1. 35/40* | PEX | Live birth but severe developmental delay |
| 2. 36/40 | BPL 8Y from 12/40, 20 U/kg 2 weekly, increasing to 30 U/kg weekly from 25/40; PEX pre- and postdelivery; LDA and LMWH | Live birth | |
| 3. 11/40 | Miscarriage | ||
| 4. 36/40 | PEX every 2 wk, increased to weekly from mid–second trimester | Live birth | |
| 4 | First trimester* | 10/7 PEX until TTP remission, continued 3×/wk PEX until delivery; LDA; LMWH | Live 34/40 |
| 5 | 17/40* | Daily PEX, LDA, LMWH, steroids, rituximab | Live 30+/40 |
| 6† | 1. 37/40 | Steroids | Stillbirth |
| 2. 32/40 | FFP and steroids | IUFD | |
| 3. 32/40 | Live birth | ||
| 4. 33/40 (twins) | IUFD 33/40 | ||
| 7 | 1. 20/40 | IUFD | |
| 2. 31/40* | Daily PEX until remission, then weekly until 37/40 and postpartum | Live birth 37/40 | |
| 3. 23/40 | Daily PEX until remission, then every 2 wk until 31/40, PEX increased to twice weekly; 5 PEX postpartum | Live birth 38/40 | |
| 8 | 1. 25/40* | IUFD | |
| 2. 35/40 | PEX every 2 wk from 12 wk | Live birth | |
| 3. 8/40 | Miscarriage | ||
| 4. 34/40 | PEX every 2 wk from 12 wk; changed to BPL 8Y from 20/40 to delivery | Live birth | |
| 9 | 40/40* | PEX, LDA | Live birth |
| 10 | 37/40* | PEX, LDA | Live birth |
| 11 | 1. 14/40 | IUFD | |
| 2. 19/40 | IUFD | ||
| 3. 20/40 | IUFD | ||
| 4. 6/40 | Miscarriage | ||
| 5. 36/40* | Daily PEX and steroids | Live birth 37/40 | |
| 6. 37/40 | LDA and LMWH throughout; PI from 10/40 every 2 wk until 20 wk, then continued weekly; 1 PEX pre- and postdelivery | Live birth | |
| 12 | 1. 38/40* | PEX, LDA | Live birth |
| 2. 37/40 | PEX every 2 wk from 12 wk, continued with PI every 2 wk from second trimester | Live birth | |
| 13 | 1. 39/40* | PEX | Live birth |
| 2. 38/40 | Weekly PI in third trimester, LMWH, and LDA | Live birth | |
| 14 | 1. 27/40 | Platelet transfusion | Live birth |
| 2. 34/40* | PEX, steroids, LDA, LMWH, IVIg | Live birth | |
| 3. 36/40 | BPL 8Y ×2/wk throughout pregnancy and 4 wk postpartum; 2× PEX predelivery | Live birth | |
| 15 | 32/40* | Daily PEX to TTP remission then weekly until delivery | Live birth 37/40 |
| 16 | 1. 20/40 (twins) | IVIg, prednisolone, platelets, PEX | IUFD 25/40 |
| 2. 39/40 | PI throughout pregnancies; platelets at delivery | Live birth | |
| 3. 37/40 | Live birth | ||
| 4. 37/40* | Live birth | ||
| 17 | 14/40* | Daily PEX until remission, then weekly PEX to delivery | Live birth 35/40 |
| 18 | (Known from positive FH) | LDA, PI every 2 wk, then weekly from 25/40 | 37/40 |
| 19 | 1. 20/40 | IUFD | |
| 2. 24/40 (twins)* | IUFD | ||
| 3. 6/40 | Miscarriage | ||
| 4. 37/40 | Plasma treatment ×2/wk from 12 wk | Live birth | |
| 20 | 33/40 | Steroids | Live birth |
| 21 | 1. 34/40 (twins) | Platelets | Live birth |
| 2. 28/40* | PEX | Live 29/40 | |
| 22 | 1. 24/40 | IUFD | |
| 2. 26/40 | IUFD | ||
| 3. 27/40 | IUFD | ||
| 4, 5, 6. 6-12/40 | 3 miscarriages | ||
| 7. 27/40 | Live birth | ||
| 8. 20/40* | LDA, LMWH, PI, PEX | IUFD 28/40 | |
| 23† | 36/40 | Live birth |